Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4309161 | 1.00 | KDM4E (0.44) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL4225527 | 1.00 | KDM4E (0.44) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL4319218 | 0.82 | KDM4E (0.47) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL5003607 | 0.82 | KDM4E (0.47) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL4319221 | 0.82 | KDM4E (0.47) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL6058015 | 0.79 | KDM4E (0.44) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL8915722 | 0.79 | KDM4E (0.44) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL10896691 | 0.78 | MAPT (0.43) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL19569878 | 0.78 | PTGS1 (0.45) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Hydrogen Sulfide SCHEMBL2230859 | 0.78 | FOLH1 (0.47) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3369430-B1 | ACUTE RESPIRATORY DISTRESS SYNDROME THERAPEUTIC AGENT | LTT BIO PHARMA CO LTD (JP) | 2021-08-11 | — | — | EP | claimed |
| US-20180320148-A1 | Acute Respiratory Distress Syndrome Therapeutic Agent | LTT BIO-PHARMA CO., LTD. (JP) | 2018-11-08 | — | — | US | claimed |
| EP-3369430-A1 | ACUTE RESPIRATORY DISTRESS SYNDROME THERAPEUTIC AGENT | LTT Bio-Pharma Co., Ltd. (JP) | 2018-09-05 | — | — | EP | claimed |
| EP-2407176-B1 | AMELIORATING AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | LTT BIO PHARMA CO LTD (JP) | 2016-10-19 | — | — | EP | claimed |
| US-20140023629-A1 | AMELIORATING AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | LTT BIO-PHARMA CO., LTD. (JP) | 2014-01-23 | — | — | US | claimed |
| US-20120034202-A1 | AMELIORATING AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | LTT BIO-PHARMA CO., LTD. (JP) | 2012-02-09 | — | — | US | claimed |
| EP-2407176-A1 | Ameliorating agent for chronic obstructive pulmonary disease | LTT Bio-Pharma Co., Ltd. (JP) | 2012-01-18 | — | — | EP | claimed |
| US-20110262420-A1 | INHALANT COMPRISING MODIFIED SUPEROXIDE DISMUTASE | LTT BIO-PHARMA CO., LTD. (JP) | 2011-10-27 | — | — | US | claimed |
| EP-2359845-A1 | INHALANT COMPRISING MODIFIED SUPEROXIDE DISMUTASE | LTT Bio-Pharma Co., Ltd. (JP) | 2011-08-24 | — | — | EP | claimed |
| US-20100143321-A1 | THERAPEUTIC COMPOSITION FOR INTERSTITUAL PNEUMONIA | LTT BIO PHARMA CO., LTD. (JP) | 2010-06-10 | — | — | US | claimed |
| EP-2123295-A1 | THERAPEUTIC AGENT FOR INTERSTITIAL PNEUMONIA | LTT Bio-Pharma Co., Ltd. (JP) | 2009-11-25 | — | — | EP | claimed |
| EP-1188445-B1 | DRUG COMPOSITION CONTAINING LECITHIN-MODIFIED SUPEROXIDE DISMUTASE | LTT BIO PHARMA CO LTD (JP) | 2007-11-21 | — | — | EP | claimed |
| US-5762929-A | SUPEROXIDE DISMUTASE CONJUGATED WITH LECITHIN | SAM RESEARCH CORPORATION (JP) | 1998-06-09 | — | — | US | claimed |
| JP-9110717-A | — | — | None | — | — | JP | disclosed |
| JP-10338645-A | — | — | None | — | — | JP | disclosed |
| US-12385017-B2 | Acute respiratory distress syndrome therapeutic agent | LTT BIO-PHARMA CO., LTD. (JP) | 2025-08-12 | — | — | US | disclosed |
| EP-2123295-A1 | THERAPEUTIC AGENT FOR INTERSTITIAL PNEUMONIA | LTT Bio-Pharma Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| JP-H10338645-A | AGENT FOR IMPROVING FUNCTIONAL DISORDER ACCOMPANIED BY CEREBROVASCULAR DISEASE | SAMU KENKYUSHO:KK | 1998-12-22 | — | — | JP | disclosed |
| US-5762929-A | SUPEROXIDE DISMUTASE CONJUGATED WITH LECITHIN | SAM RESEARCH CORPORATION (JP) | 1998-06-09 | — | — | US | disclosed |
| JP-H09110717-A | THERAPEUTIC AGENT FOR LUPUS NEPHRITIS | SAMU KENKYUSHO:KK | 1997-04-28 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140023629-A1 | AMELIORATING AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | MPO, LPO, CAT | KDM4E 3294/4885MAPT 3877/4885THRB 3749/4885 |
| US-20120034202-A1 | AMELIORATING AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | MPO, LPO, CAT | KDM4E 3373/4885MAPT 3951/4885THRB 3910/4885 |
| US-12385017-B2 | Acute respiratory distress syndrome therapeutic agent | MPO, LPO, GPX4 | KDM4E 3957/4885MAPT 4406/4885THRB 4506/4885 |
| US-20180320148-A1 | Acute Respiratory Distress Syndrome Therapeutic Agent | MPO, LPO, GPX4 | KDM4E 3957/4885MAPT 4406/4885THRB 4506/4885 |
| US-20100143321-A1 | THERAPEUTIC COMPOSITION FOR INTERSTITUAL PNEUMONIA | MPO, MMP1, LPO | KDM4E 3325/4885MAPT 1795/4885THRB 4134/4885 |
| US-20110262420-A1 | INHALANT COMPRISING MODIFIED SUPEROXIDE DISMUTASE | MPO, SOD1, SGMS1 | KDM4E 3120/4885MAPT 2574/4885THRB 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.